Post by Mediamedic

🎗️🌍 ASCO Spotlight | Professors Jun Guo and Shilpa Gupta, MD on the Landmark 3.5-Year EV-302 Results At ASCO 2026, Professors Jun Guo and Shilpa Gupta discussed the latest long-term follow-up data from the pivotal EV-302 trial, further reinforcing the transformative impact of enfortumab vedotin plus pembrolizumab (EV+P) in advanced urothelial carcinoma. 📖 Read more to explore Professors Guo and Gupta’s perspectives on the latest EV-302 data, the evolving role of ADC-immunotherapy combinations, and how these advances are reshaping the future of precision treatment in urothelial carcinoma. #JunGuo #ShilpaGupta #ASCO2026 #EV302 #EnfortumabVedotin #Pembrolizumab #UrothelialCarcinoma #ADC #Immunotherapy #Oncology